Categories: Market

Moberg Pharma and Padagis sign agreement for MOB-015 in Israel

Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian territories. Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.

Padagis will conduct registration activities in Israel, and will be marketing, distributing and selling MOB-015 in Israel and the Palestinian territories upon completion of registration.

This is the sixth commercial agreement for MOB-015, this time with a leading provider of extended topical and other specialty pharmaceuticals in Israel. We look forward to work with Padagis and making MOB-015 available in Israel, contributing to our vision of making MOB-015 the leading nail fungus treatment worldwide”, says Anna Ljung, CEO of Moberg Pharma.

As a leading pharmaceutical company in Israel, Padagis Israel welcomes the signing of this agreement with Moberg Pharma and look forward to a fruitful cooperation and collaboration between the two companies”, says Shlomi Leibovich, SVP & CEO of Padagis Israel.

According to Moberg Pharma’s market intelligence, the Israelian market for topical drugs for onychomycosis amounts to approximately €6.5 million.


Published by

Recent Posts

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company")  announced its…

5 months ago

Staffordshire University team make shortlist at higher education Oscars

Staffordshire University’s Library and Learning Services team has been shortlisted for an award at the…

7 months ago

Nidec Signs Joint Venture Agreement with Norwegian Semi-Solid Lithium-Ion Battery Manufacturer FREYR Battery

On August 30, 2022 (Japan Standard Time), Nidec Corporation (“Nidec”) (TSE: 6594; OTC US: NJDCY)…

7 months ago

Rapid Micro Biosystems Announces Review of Strategic Alternatives to Maximize Shareholder Value

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing…

7 months ago

Venus Concept Announces Second Quarter of Fiscal Year 2022 Financial Results; Updates Fiscal Year 2022 Revenue Guidance

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology…

7 months ago

NNT and Polygiene team up to create new frontline workwear uniforms for health professionals

If you work in a high-pressure environment, you want to feel fresh and comfortable. When…

8 months ago